For years, AbbVie (NYSE: ABBV) was known primarily for immunology. Humira built the company into a pharmaceutical giant, and newer blockbusters Skyrizi and Rinvoq have helped replace much of the revenue lost to biosimilar competition. Now the company's got another iron in the fire -- neuroscience -- and it's no slouch.
Management now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. That's a remarkable figure when you consider that the portfolio generated $10.8 billion last year and continues to grow at a double-digit pace.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Unlike some pharmaceutical franchises that depend on a single blockbuster, AbbVie's neuroscience business has become increasingly diversified. During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion. Schizophrenia and bipolar disorder drug Vraylar generated $1.07 billion, therapeutic Botox contributed $1.04 billion, and migraine drugs Ubrelvy and Qulipta combined for $742 million in quarterly sales. Parkinson's disease therapy Vyalev added another $256 million.
The fastest-growing part of AbbVie's neuroscience business may be migraine. Combined sales rose 22.6% year over year as Ubrelvy and Qulipta continued gaining traction with physicians addressing both acute migraine attacks and migraine prevention.
#year #billion #revenue #million
Management now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. That's a remarkable figure when you consider that the portfolio generated $10.8 billion last year and continues to grow at a double-digit pace.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Unlike some pharmaceutical franchises that depend on a single blockbuster, AbbVie's neuroscience business has become increasingly diversified. During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion. Schizophrenia and bipolar disorder drug Vraylar generated $1.07 billion, therapeutic Botox contributed $1.04 billion, and migraine drugs Ubrelvy and Qulipta combined for $742 million in quarterly sales. Parkinson's disease therapy Vyalev added another $256 million.
The fastest-growing part of AbbVie's neuroscience business may be migraine. Combined sales rose 22.6% year over year as Ubrelvy and Qulipta continued gaining traction with physicians addressing both acute migraine attacks and migraine prevention.
#year #billion #revenue #million
3 months ago
